Aktuellt
SENASTE
The Curasight Q3 2023 report highlights notable achievements, including a partnership with Curium and positive preclinical data for uTREAT in non-small cell lung cancer. The investigator-initiated phase II study of uTRACE in brain cancer supports the versatility of Curasight's uPAR theranostic platform across various tumor types. We make no adjustments to our model and maintain our rNPV-SOTP mid-point value of DKK 54.
LÄS MER
